DNSP-11
Limited researchGDNF-Derived Peptide | Dopaminergic Neuroprotection
DNSP-11 is an 11-amino acid peptide derived from the pro-domain of glial cell line-derived neurotrophic factor (GDNF).
Molecular & research data
- Sequence
- Pro-Pro-Glu-Ala-Pro-Ala-Glu-Asp-Arg-Ser-Leu
- Molecular weight
- ~1200 Da
- Half-life
- Not well characterized
- Primary targets
- dopamine-receptor
- Routes (research)
- Nasal, Injectable
- Storage
- Lyophilized: -20C long-term; Reconstituted: 2-8C, use within 4 weeks
Overview
DNSP-11 is an 11-amino acid peptide derived from the pro-domain of glial cell line-derived neurotrophic factor (GDNF). It was designed to capture the neuroprotective properties of GDNF while avoiding the limitations of the full-length protein, including poor blood-brain barrier penetration, off-target effects, and manufacturing complexity. Preclinical research demonstrates that DNSP-11 protects and stimulates dopaminergic neurons, making it a compound of significant interest for Parkinson’s disease research and biohacking communities focused on dopamine system health.
Mechanism of action
DNSP-11 acts on dopaminergic neurons through mechanisms distinct from full-length GDNF. Rather than binding to the canonical GFRalpha1/RET receptor complex, DNSP-11 appears to engage alternative signaling pathways to promote dopaminergic neuron survival, stimulate dopamine release, and protect against neurotoxin-induced damage. It enhances tyrosine hydroxylase expression (the rate-limiting enzyme in dopamine synthesis) and supports mitochondrial function in dopaminergic neurons.
Key research findings
- Protects dopaminergic neurons from neurotoxic insults
- Stimulates dopamine production via tyrosine hydroxylase upregulation
- Smaller molecule with improved bioavailability compared to full GDNF
- Does not require GFRalpha1/RET receptor complex for activity
- Preclinical evidence for neuroprotection in Parkinson’s disease models
- Compatible with intranasal and subcutaneous administration
Research applications
Neuroprotection
- Dopaminergic Neuron Protection — Protects dopamine-producing neurons from neurotoxin-induced damage in preclinical Parkinson’s disease models.
- Tyrosine Hydroxylase Support — Upregulates tyrosine hydroxylase expression, supporting the rate-limiting step in dopamine biosynthesis.
- Mitochondrial Function — Supports mitochondrial health in dopaminergic neurons, which is often compromised in neurodegenerative conditions.
Cognitive
- Motivation and Drive — Biohacker reports suggest improvements in baseline motivation and drive, consistent with dopaminergic system support.
- Mood Baseline — Anecdotal reports of improved mood stability and emotional baseline, likely mediated through dopamine pathway optimization.
DNSP-11 FAQ
Is DNSP-11 easier to use than full-length GDNF protein?+
Yes, DNSP-11 is an 11-amino acid peptide fragment of GDNF's pro-domain that offers several advantages over full-length GDNF: better blood-brain barrier penetration, avoidance of off-target effects, simpler manufacturing, and intranasal administration feasibility. It captures neuroprotective benefits while being more practical.
Can DNSP-11 improve baseline motivation and dopamine levels in healthy people?+
Anecdotal reports from biohackers suggest DNSP-11 improves baseline motivation, drive, and mood stability in healthy individuals. These effects likely result from dopaminergic neuron support via tyrosine hydroxylase upregulation, though formal human studies on motivation/drive in non-disease populations are lacking.
What's the best way to administer DNSP-11—nasal or injectable?+
Intranasal appears most popular in biohacking communities as it offers potential direct CNS delivery via olfactory transport, bypassing the blood-brain barrier. Subcutaneous injection provides reliable systemic absorption but relies on BBB penetration. Nasal administration is more convenient but may cause irritation in some users.
How long can DNSP-11 be used continuously, or does it need cycling?+
Human data on cycling versus continuous use is extremely limited. Most protocols use 4-6 week cycles followed by breaks, though DNSP-11's neurotrophic mechanism differs from stimulants that cause tolerance. Conservative approach suggests cycling to prevent potential receptor desensitization, though long-term effects remain understudied.
References
- [1]DNSP-11 Is a Novel GDNF Pro-Peptide That Protects Dopaminergic Neurons in a Rat Model of Parkinson's DiseaseNeuroscience Letters
- [2]Dopamine Neuron Stimulating Peptide-11 (DNSP-11): A Novel, Small Peptide That Provides Long-Term Protection in a Rat Model of Parkinson's DiseaseNeuropharmacology
- [3]DNSP-11 Induces Behavioral Recovery and Nigrostriatal Neurochemical Changes in a Unilateral 6-OHDA Rat Model of Parkinson's DiseaseSociety for Neuroscience Abstract
- [4]Identification of Two Novel Peptides from the GDNF Pro-Domain That Bind to GFRalpha1Analytical Biochemistry
- [5]DNSP-11 Induces Behavioral Recovery and Nigrostriatal Neurochemical ChangesPeptides
Related peptides
Last reviewed: 2026-06-26. Information is provided for research and educational reference only — see our disclaimer.